Genetics of Gastric Cancer.
Gastric cancer represents a major cause of cancer mortality worldwide despite a declining incidence. New molecular classification schemes developed from genomic and molecular analyses of gastric cancer have provided a framework for understanding this heterogenous disease, and early findings suggest these classifications will be relevant for designing and implementing new targeted therapies. The success of targeted therapy and immunotherapy in breast cancer and melanoma, respectively, has not been duplicated in gastric cancer, but trastuzumab and ramucirumab have demonstrated efficacy in select populations. New markers that predict therapeutic response are needed to improve patient selection for both targeted and immunotherapies.
Department of Surgery, Barnes-Jewish Hospital and Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8109, St Louis, MO 63110, USA.
Matthew S
MS
Strand
Department of Medicine, Barnes-Jewish Hospital and Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO 63110, USA.
Albert Craig
AC
Lockhart
Department of Surgery, Barnes-Jewish Hospital and Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8109, St Louis, MO 63110, USA. Electronic address: fieldsr@wudosis.wustl.edu.
Ryan C
RC
Fields
D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D055088:Early Detection of Cancer / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors; D005743:Gastrectomy / Q000379:methods / Q000401:mortality; D053823:Hedgehog Proteins / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D020935:MAP Kinase Signaling System / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000379:methods / Q000401:mortality; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D013274:Stomach Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D001688:Biological Products; D066246:ErbB Receptors; D016222:Fibroblast Growth Factor 2; D053823:Hedgehog Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A
Gastric adenocarcinoma; Gastric cancer; Genetics; Hereditary gastric cancer syndromes; Immunotherapy; Prophylactic gastrectomy; Targeted therapy